Acute facial nerve palsy occur in 10-20/100 000 children/year in Sweden. About 20 % of these children will have persistent symptoms with excessive tear secretion, drooling and social problems due to asymmetry in the face. Studies on cortisone treatment to adult patients with acute facial nerve palsy have shown beneficial effects, but no studies with strong quality have been performed in children. Investigators will perform a double-blind randomized placebo-controlled multicenter trial on children with acute facial nerve palsy. Participants will be recruited consecutively at 9-12 study centers in Sweden during 2019-2020. Oral cortisone (prednisolone) 1 mg/kg x 1 in 10 days (or placebo) will be started on admission. Clinical data, including recovery will be followed-up until 12 months. The primary outcome is defined as total recovery of the facial nerve palsy, measured with the House-Brackmann scale (grade 1) at 12-months follow-up. The overall purpose is to assess the utility of cortisone treatment given to children with acute facial nerve palsy in this study. If the total recovery rate is significantly improved in the prednisolone group as compared to the placebo group, prednisolone treatment will be introduced in clinical practice for children with acute facial nerve palsy in order to reduce the risk of persistent symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
500
Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
Placebo tablets with identical appearance to the experimental drug
Barn- och ungdomsmedicin
Falun, Dalarna County, Sweden
RECRUITINGBarn och ungdomskliniken, Länssjukhuset
Kalmar, Region Kalmar, Sweden
RECRUITINGBarnkliniken, Skaraborgs sjukhus
Skövde, Västra Götalands Region, Sweden
RECRUITINGBarnmedicin Drottning Silvias Barn- och Ungdomssjukhus Östra Sjukhuset
Gothenburg, Sweden
RECRUITINGBarn- och ungdomsmedicinska kliniken
Jönköping, Sweden
RECRUITINGBarn- och ungdomsmottagning
Karlskrona, Sweden
RECRUITINGHKH Kronprinsessan Viktorias Barn- och ungdomssjukhus
Linköping, Sweden
RECRUITINGAkutmottagning för barn, Skåne Universitets sjukhus
Lund, Sweden
RECRUITINGBarnakuten i Malmö, Skåne Universitets sjukhus
Malmo, Sweden
RECRUITINGBarn- och ungdomskliniken, Vrinnevi sjukhuset
Norrköping, Sweden
RECRUITING...and 5 more locations
House-Brackmann scale
Total recovery in the two treatment groups measured with the House-Brackmann scale. The House-Brackmann scale (I is normal function and VI is total loss of function) is chosen as primary outcome measure since it is an objective instrument, easy to perform and the one most frequently used in previous studies. The time point 12 months for evaluation of total recovery is chosen as no further improvement of the facial nerve function is expected after 12 months.
Time frame: At 12 months (+/- 2 weeks) after inclusion
Sunnybrook facial grading system
Total recovery in the two treatment groups measured with the Sunnybrook scale. The Sunnybrook scale (100 is normal function and 0 is total loss of function) is another objective scale for grading the facial nerve function. It will be used as secondary outcome measure. It is easy to perform and has been used in previous studies in children. It correlates well to the House-Brackmann scale.
Time frame: At 12 months (+/- 2 weeks) after inclusion
Facial Disability Index (FDI)
Disease-specific Quality-of-Life assessment scale, with 5 functional domains (5 means no probelms and 2 or 1 means problems all the time) and 5 social domains (6 means problems all the time and 1 means no problems at all)
Time frame: At 12 months (+/- 2 weeks) after inclusion
Facial Clinimetric Evaluation (FaCE) Scale
Disease-specific Quality-of-Life assessment scale, with 15 functional and social domains (1 means problems all the time and 5 means no problems at all).
Time frame: At 12 months (+/- 2 weeks) after inclusion
Synkinesis Assessment Questionnaire (SAQ)
Subjective grading of synkinesis symptoms with 9 functional domains (1 means no problems at all and 5 means problems all the time).
Time frame: At 12 month (+/- 2 weeks) after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.